Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;6(4):227-33.
doi: 10.14740/jocmr1858w. Epub 2014 May 22.

Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review

Affiliations
Review

Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review

Dimitrios Velissaris et al. J Clin Med Res. 2014 Aug.

Abstract

The objective of the paper is to review the literature and provide recommendations for use of aminoglycoside antibiotics in critically ill obese patients. Literature search in PubMed for all articles on the use of aminoglycosides in critically ill obese patients was conducted, and all articles related to pharmacokinetics in obesity were reviewed. Bibliographies of all searched manuscripts were also reviewed in an attempt to find additional references. Although aminoglycoside pharmacokinetics have been described in detail, data on aminoglycoside use and appropriate dose modification in critically ill obese patients are very limited. Knowledge on aminoglycoside pharmacokinetics and use in critically ill obese patients is incomplete. Pathophysiologic changes in obesity can result in sub- or supra-therapeutic aminoglycoside plasma concentrations, especially in the presence of sepsis. Rigorous clinical studies are needed to establish aminoglycoside dosing guidelines in critically ill obese patients with sepsis.

Keywords: Amikacin; Aminoglycoside; Critical illness; Gentamicin; Obesity; Pharmacokinetics; Sepsis; Tobramycin.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schwartz SN, Pazin GJ, Lyon JA, Ho M, Pasculle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978;138(4):499–505. doi: 10.1093/infdis/138.4.499. - DOI - PubMed
    1. Blouin RA, Mann HJ, Griffen WO, Jr., Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 1979;26(4):508–512. - PubMed
    1. Bauer LA, Blouin RA, Griffen WO, Jr., Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm. 1980;37(4):519–522. - PubMed
    1. Korsager S. Administration o gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol. 1980;18(12):549–553. - PubMed
    1. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–647. doi: 10.1007/BF00542215. - DOI - PubMed

LinkOut - more resources